The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free ...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...

In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

The experimental drug erenumab (AMG 334, Amgen and Novartis) is effective and safe in patients with episodic migraine in whom previous treatments have failed, results of a new phase 3b trial have ...

Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...